Weighing up the balance in the data disclosure debate
This article was originally published in Scrip
Executive Summary
Companies planning to submit EU approval applications from January 2014 should be aware that most of the clinical trial data in the dossier are likely to be made public as soon as a decision on marketing authorization has been taken.